Department of Pathology ANNUAL REPORT 2009 - University of ...

18. Gibson C (PI)
Health Canada
Ozone Neurotoxicity
11/1/2004 to 12/31/2008
19. Gomez JA (Co-I), Moussa M (Co-I)
CIHR Team in Image Guided Prostate
Cancer Management
Histopathologic Validation of Pre-operative
Prostate Cancer Imaging
$ 4,642,805
4/1/2008 to 3/31/2013
20. Hammond RR (PI)
Ontario Institute for Cancer Research,
LHSC-OICR Tumour Bank
$150,000 annually
1/1/2004 to 12/31/2009
21. Khan ZA (PI)
Lawson Health Research Institute
Vascular progenitor cells in diabetic
complications
$13,000
12/1/2007 to 12/31/2009
22. Khan ZA (PI)
LHSC/Multi Organ Transplant Program
Circulating Stem Cells for Vascular
Regeneration
$44,500
5/1/2008 to 4/30/2009
23. McLachlin CM (Co-I)
CIHR
Cervical Cancer Screening in the era of
HPV vaccinations: using mathematical and
economic models to guide screening policy
$228,000
7/1/2008 to 12/31/2011
24. Xuan J (PI), Moussa M (Co-I)
CIHR
Molecular diagnosis and therapy of
prostate cancer by UTMD (ultrasound
targeted mirububbles destruction)
$542,449
1/1/2008 to 12/31/2011
25. Xuan J (PI), Moussa M (Co-I)
CIHR
Micro- and molecular imaging for
preclinical trials in genetically engineered
mouse prostate cancer models.
$114,554
1/1/2005 to 12/31/2008
26. Ramsay DA (PI), Megyesi J (Co-Director)
Brain Tumour Foundation
Canadian Brain Tumour Tissue Bank
$80,000
1/1/2008 to 12/31/2008
27. Rizkalla K (Co-I)
Glaxo Smith Kline
Single arm open label study with
Tositusimab I-131 radio-radio labeled
iodine in NHL patients previously having
had received Rituzimab
$14,750
1/1/2008 to 12/31/2008
28. Rakovitch E (PI), Tuck AB (Co-I)
Canadian Breast Cancer Research Alliance
Ductal carcinoma in situ: a population
based analysis.
$254,875
1/1/2007 to 12/31/2012
29. Chambers A (PI), Tuck AB (Co-I)
CIHR
Supplement to a 5-year CIHR award
MOP42511.
$50,000
1/1/2009 to 12/31/2010
30. Chambers A (PI), Tuck AB (Co-I)
CIHR
Steps in metastasis: Identifying
therapeutic targets.
$134,825
1/1/2005 to 12/31/2010
31. Tuck AB (PI), Chambers A (Co-I)
London Regional Cancer Program
Pre-signaling targets to block malignancy-
promoting effects of osteopontin on breast
cancer.
$49,884
1/1/2009 to 12/31/2010
32. Koropatnick J (PI), Tuck AB (Co-I)
CIHR
London strategic training initiative in cancer
research and technology transfer.
$300,000
1/1/2003 to 12/31/2009
33. Tuck AB (PI), Rodenhiser (Co-I)
Canadian Breast Cancer Research Alliance
Modeling of critical steps in mammary
tumor progression in 3D culture and in
vivo.
$432,252
1/1/2005 to 12/31/2008
Department of Pathology Annual Report 2009 | 45